85%+ of Patients Have Strong Coverage for Herceptin 16,20-22*†

Understand your choice: request a coverage map for your practice or region

Legacy of Succcess icon

Learn Herceptin's Legacy

Learn about Herceptin’s legacy of treating HER2-positive breast cancer and metastatic gastric cancer.

See our legacy

Syringe icon

A Subcutaneous Option

Learn about Herceptin HYLECTA(trastuzumab and hyaluronidase-oysk), a subcutaneous trastuzumab treatment option for eligible HER2+ patients. 5

Get treatment details

*Insurer/payer policies are subject to change. The completion and submission of coverage or reimbursement-related documentation are the responsibility of the patient and the healthcare provider. Genentech makes no guarantee concerning coverage or reimbursement for any service or item. Inclusion of a plan or product is not intended to imply a recommendation of a particular plan or product. Coverage percentage shown is a weighted average based on national patients treated for Herceptin.
As of 01/01/2021, national coverage for Herceptin is 85%+.